{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T20:16:22Z","timestamp":1789416982497,"version":"build-2803163510"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T00:00:00Z","timestamp":1768694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 2017"],"award-info":[{"award-number":["IG 2017"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["20244"],"award-info":[{"award-number":["20244"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020581","name":"AIRC Foundation for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019487","name":"Bone Health and Osteoporosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019487","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.ijbiomac.2026.150375","type":"journal-article","created":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T15:41:35Z","timestamp":1768750895000},"page":"150375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"P2","title":["High-payload trastuzumab\u2013drug conjugates achieved through hydrophilic Y-shaped pendant PEG linkers for a potent and selective antitumor response"],"prefix":"10.1016","volume":"343","author":[{"given":"Benedetta","family":"Campara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Tedeschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Grigoletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gabbia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Zanotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marika","family":"Salvalaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nouran Said Fathalla","family":"Zahran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minori","family":"Takino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kota","family":"Tange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"De Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Pasut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijbiomac.2026.150375_bb0005","series-title":"The Ever-Increasing Importance of Cancer as a Leading Cause of Premature Death Worldwide","first-page":"3029","author":"Bray","year":"2021"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0010","series-title":"Chemotherapy and the War on Cancer","volume":"5","author":"Chabner","year":"2005"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0015","doi-asserted-by":"crossref","first-page":"6007","DOI":"10.1097\/JS9.0000000000001712","article-title":"A commentary on \u201cComparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, large-sample informatics study\u201d","volume":"110","author":"Yang","year":"2024","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0020","first-page":"1","article-title":"Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation","volume":"13","author":"Bin Guo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0025","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Publ. Group"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0030","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","article-title":"Historical review CAR T cells: continuation in a revolution of immunotherapy","volume":"21","author":"Singh","year":"2020","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0035","series-title":"Personalized Vaccines for Cancer Immunotherapy","first-page":"1355","volume":"1360","author":"Tyzzer","year":"2018"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0040","series-title":"Targeting Cancer with mRNA \u2013 Lipid Nanoparticles: Key Considerations and Future Prospects","first-page":"739","volume":"20","author":"Kon","year":"2023"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0045","first-page":"1","article-title":"The evolution of polymer conjugation and drug targeting for the delivery of proteins and bioactive molecules","author":"Grigoletto","year":"2020","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0050","doi-asserted-by":"crossref","first-page":"3796","DOI":"10.1002\/anie.201307628","article-title":"Antibody-drug conjugates: an emerging concept in cancer therapy","volume":"53","author":"Chari","year":"2014","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0055","first-page":"1","article-title":"Antibody drug conjugates in the clinic","author":"Udofa","year":"2024","journal-title":"Bioeng. Transl. Med."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0060","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody\u2013drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody\u2013Drug Conjugates (ADCs): current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0070","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/bcp.15888","article-title":"A first-in-human study of the novel immunology antibody\u2013drug conjugate, ABBV-3373, in healthy participants","volume":"90","author":"D\u2019Cunha","year":"2024","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0075","unstructured":"L.N. Tumey, Antibody-Drug Conjugates Methods and Protocols Methods in Molecular Biology 2078, n.d. http:\/\/www.springer.com\/series\/7651."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0080","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1021\/acsinfecdis.2c00492","article-title":"Development of host-cleavable antibody-bactericide conjugates against extracellular pathogens","volume":"9","author":"O\u2019Leary","year":"2023","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/advs.202301340","article-title":"Antibody-drug conjugates to treat bacterial biofilms via targeting and extracellular drug release","volume":"10","author":"Tvilum","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0090","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1021\/acs.bioconjchem.7b00008","article-title":"Tocilizumab-alendronate conjugate for treatment of rheumatoid arthritis","volume":"28","author":"Lee","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188849","article-title":"Antibody-drug conjugates in breast cancer: marching from HER2-overexpression into HER2-low","volume":"1878","author":"Fan","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0100","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1158\/1535-7163.MCT-14-0798","article-title":"High turnover of tissue factor enables efficient intracellular delivery of antibody-drug conjugates","volume":"14","author":"De Goeij","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0105","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","article-title":"Antibody conjugate therapeutics: challenges and potential","volume":"17","author":"Teicher","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies \u2014 a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1200\/EDBK_280775","article-title":"Antibody-drug conjugates: patient and treatment selection","author":"Makawita","year":"2020","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0120","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1016\/j.apsb.2023.06.015","article-title":"Antibody\u2013drug conjugates: recent advances in payloads","volume":"13","author":"Wang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0125","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1021\/bc400439x","article-title":"Auristatin antibody drug conjugate physical instability and the role of drug payload","volume":"25","author":"Adem","year":"2014","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0130","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1021\/acs.molpharmaceut.8b00177","article-title":"Impact of payload hydrophobicity on the stability of antibody-drug conjugates","volume":"15","author":"Buecheler","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0135","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.xphs.2018.03.022","article-title":"Biophysical properties and heating-induced aggregation of lysine-conjugated antibody-drug conjugates","volume":"107","author":"Gandhi","year":"2018","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0140","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1021\/bc400182x","article-title":"Investigation into temperature-induced aggregation of an antibody drug conjugate","volume":"24","author":"Beckley","year":"2013","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0145","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","article-title":"Fc\u03b3 receptor-dependent internalization and off-target cytotoxicity of antibody-drug conjugate aggregates","volume":"39","author":"Aoyama","year":"2022","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0150","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0155","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1021\/acs.bioconjchem.7b00062","article-title":"Effects of drug-antibody ratio on pharmacokinetics, biodistribution, efficacy, and tolerability of antibody-maytansinoid conjugates","volume":"28","author":"Sun","year":"2017","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0160","doi-asserted-by":"crossref","first-page":"7063","DOI":"10.1158\/1078-0432.CCR-04-0789","article-title":"Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate","volume":"10","author":"Hamblett","year":"2004","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0165","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.pharmthera.2019.04.008","article-title":"Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates","volume":"200","author":"Mahalingaiah","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0170","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.bmcl.2005.09.081","article-title":"Dipeptide-based highly potent doxorubicin antibody conjugates","volume":"16","author":"Jeffrey","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0175","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1021\/acsmedchemlett.6b00062","article-title":"Design and synthesis of tesirine, a clinical antibody-drug conjugate pyrrolobenzodiazepine dimer payload","volume":"7","author":"Tiberghien","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0180","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2024.08.049","article-title":"Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates","volume":"375","author":"Tedeschini","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0185","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1248\/cpb.43.1931","article-title":"Synthesis of carboxymethylpullulan-peptide-doxorubicin conjugates and their properties","volume":"43","author":"Nogusa","year":"1995","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0190","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1248\/bpb.20.1061","article-title":"Antitumor effects and toxicities of carboxymethylpullulan-peptide-doxorubicin conjugates","volume":"20","author":"Nogusa","year":"1997","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0195","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0200","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11113080","article-title":"Lysosomal-cleavable peptide linkers in antibody\u2013drug conjugates","volume":"11","author":"Balamkundu","year":"2023","journal-title":"Biomedicines"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0205","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1021\/bc9001097","article-title":"Design, synthesis, and biological evaluation of antibody-drug conjugates comprised of potent camptothecin analogues","volume":"20","author":"Burke","year":"2009","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0210","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1158\/1535-7163.MCT-16-0343","article-title":"Optimization of a PEGylated glucuronide-monomethylauristatin E linker for antibody-drug conjugates","volume":"16","author":"Burke","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0215","doi-asserted-by":"crossref","first-page":"942","DOI":"10.18632\/oncotarget.27512","article-title":"Erratum: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) (Oncotarget (2015) 6 (22496\u201322512) DOI: 10.18632\/oncotarget.4318)","volume":"11","author":"Goldenberg","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0220","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1021\/bc025536j","article-title":"Cathepsin B-labile dipeptide linkers for lysosomal release of doxorubicin from internalizing immunoconjugates: model studies of enzymatic drug release and antigen-specific in vitro anticancer activity","volume":"13","author":"Dubowchik","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0225","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/nbt832","article-title":"Development of potent monoclonal antibody auristatin conjugates for cancer therapy","volume":"21","author":"Doronina","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0230","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1158\/1078-0432.843.11.2","article-title":"In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate","volume":"11","author":"Sanderson","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0235","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1039\/C9SC00285E","article-title":"Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates","volume":"10","author":"Viricel","year":"2019","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114932","article-title":"Reducing the antigen-independent toxicity of antibody-drug conjugates by minimizing their non-specific clearance through PEGylation","volume":"392","author":"Simmons","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0245","series-title":"PEGylation of Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics of Antibody-Drug Conjugates","author":"Long","year":"2024"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0250","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1039\/D2SC05678J","article-title":"Compact hydrophilic electrophiles enable highly efficacious high DAR ADCs with excellent in vivo PK profile","volume":"14","author":"Ochtrop","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0255","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.jconrel.2024.01.012","article-title":"Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer","volume":"366","author":"Douez","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0260","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0265","doi-asserted-by":"crossref","unstructured":"D.R. Dar, D.L. Distribution, Chapter 17, 1045 (n.d.) 275\u2013283. doi:https:\/\/doi.org\/10.1007\/978-1-62703-541-5.","DOI":"10.1007\/978-1-62703-541-5"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/adhm.202301650","article-title":"Anti-HER2 super stealth immunoliposomes for targeted-chemotherapy","volume":"12","author":"Canato","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0275","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cmpb.2010.01.007","article-title":"PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft excel","volume":"99","author":"Zhang","year":"2010","journal-title":"Comput. Methods Programs Biomed."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0280","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1021\/acs.bioconjchem.6b00375","article-title":"Characterization of reactions between water-soluble trialkylphosphines and thiol alkylating reagents: implications for protein-conjugation reactions","volume":"27","author":"Kantner","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0285","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody\u2013drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0290","doi-asserted-by":"crossref","first-page":"3347","DOI":"10.1016\/S0960-894X(98)00610-6","article-title":"Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (taxol\u00ae), mitomycin C and doxorubicin","volume":"8","author":"Dubowchik","year":"1998","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0295","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1039\/C8CS00676H","article-title":"Cleavable linkers in antibody-drug conjugates","volume":"48","author":"Bargh","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0300","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1002\/cncr.35205","article-title":"Antibody\u2013drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer","volume":"130","author":"Qu","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.ijbiomac.2026.150375_bb0305","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102989","article-title":"Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer","volume":"9","author":"Curigliano","year":"2024","journal-title":"ESMO Open"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026003016?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813026003016?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T07:04:59Z","timestamp":1773990299000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813026003016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":61,"alternative-id":["S0141813026003016"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150375","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-payload trastuzumab\u2013drug conjugates achieved through hydrophilic Y-shaped pendant PEG linkers for a potent and selective antitumor response","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2026.150375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"150375"}}